A newly launched startup is building upon innovations developed over several years at the Wyss Institute for Biologically Inspired Engineering at Harvard University, Harvard John A. Paulson School of Engineering & Applied Sciences (SEAS), and Brigham and Women’s Hospital (Brigham) to engineer functional kidney tissue for renal repair and replacement therapy. San Diego-based Trestle Biotherapeutics has been granted a license, by Harvard’s Office of Technology Development (OTD), to commercialize a suite of stem cell- and 3D bioprinting-based kidney regenerative medicine technologies developed at Harvard’s Wyss Institute, SEAS, and Brigham. Founded in 2020, Trestle is led by Ben Shepherd, Ph.D. and Alice Chen, Ph.D., both with deep experience in commercial efforts focused in stem cell biology, tissue engineering, regenerative medicine, and 3D bioprinting.
